Compounds > abbott 41988
Page last updated: 2024-11-10

abbott 41988

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Abbott 41988: tetrahydropyridobenzopyran derived from cannabinoid nucleus; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3085018
CHEMBL ID303312
SCHEMBL ID11706837
MeSH IDM0061828

Synonyms (23)

Synonym
unii-68gdt58m65
68gdt58m65 ,
52763-30-1
bw29y
2h-(1)benzopyrano(4,3-c)pyridin-10-ol, 8-(4-(4-fluorophenyl)-1-methylbutyl)-1,3,4,5-tetrahydro-5,5-dimethyl-2-(2-propynyl)-
OPREA1_199590
CHEMDIV1_024240
a-41988
abbott 41988
TCMDC-124277 ,
CHEMBL303312 ,
HMS655N18
bdbm50000712
7-[4-(4-fluoro-phenyl)-1-methyl-butyl]-10,10-dimethyl-3-prop-2-ynyl-2,3,4,10-tetrahydro-1h-9-oxa-3-aza-phenanthren-5-ol
8-[5-(4-fluorophenyl)pentan-2-yl]-5,5-dimethyl-2-prop-2-ynyl-3,4-dihydro-1h-chromeno[4,3-c]pyridin-10-ol
SCHEMBL11706837
abbott-41988
Q4646873
DTXSID30967213
8-[5-(4-fluorophenyl)pentan-2-yl]-5,5-dimethyl-2-(prop-2-yn-1-yl)-1,3,4,5-tetrahydro-2h-[1]benzopyrano[4,3-c]pyridin-10-ol
5,5-dimethyl-8-(5-(4-fluorophenyl)-2-pentyl)-10-hydroxy-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1)benzopyrano(3,4-d)pyridine
2h-(1)benzopyrano(4,3-c)pyridin-10-ol, 8-(4-(4-fluorophenyl)-1-methylbutyl)-1,3,4,5-tetrahydro-5,5-dimethyl-2-(2-propyn-1-yl)-
2h-[1]benzopyrano[4,3-c]pyridin-10-ol, 8-[4-(4-fluorophenyl)-1-methylbutyl]-1,3,4,5-tetrahydro-5,5-dimethyl-2-(2-propyn-1-yl)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet-activating factor receptorCavia porcellus (domestic guinea pig)Ki3.25000.00040.33863.2500AID157897
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (93)

Assay IDTitleYearJournalArticle
AID1149183Antisecretory activity in Sprague-Dawley rat assessed as decrease in acid output at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID181013percentage decrease in heart rate after 6 hr at a dose of 30 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193527Percentage decrease in systolic blood pressure after 6 hr at 0.3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193546The compound was tested for methamphetamine antagonism in rat at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149145Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 10 mg/kg, po after 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150028Hyperexcitability activity in Long-Evens black-hooded rat assessed as behavioral responses to tactile stimulation at 10 mg/kg, po1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1149213Antiulcer activity in albino Sprague-Dawley rat stress ulcer model assessed as prevention of stress-induced gastric lesions by measuring ulcer index score at 10 mg/kg, po administered 30 mins prior to stress measured after 4 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID181004percentage decrease in heart rate after 4 hr at a dose of 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149201Antidiarrheal activity in Charles River rat assessed as inhibition of castor oil-induced diarrhea by measuring protected animals at 0.5 mg/kg, po administered 1 hr prior to castor oil challenge measured after 1 hr relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193391Percentage decrease in systolic blood pressure after 24 hr at 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149149Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 0.3 mg/kg, po after 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193394Percentage decrease in systolic blood pressure after 4 hr at 0.3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149144Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 10 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149133Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 10 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID180997percentage decrease in heart rate after 4 hr at a dose of 1 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1150017Antianxiety activity in po dosed beagle-like dog assessed as minimum dose required to produce moderate ataxia1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID193528Percentage decrease in systolic blood pressure after 6 hr at 1 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149104Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 1 mg/kg, po after 2 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149178Antisecretory activity in Sprague-Dawley rat assessed as decrease in acidity at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID140546The compound was tested for activity to decrease fighting in mouse at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1150008Antidepressant activity in mouse assessed as potentiation of (+/-)Dopa-induced motor responses at 5 mg/kg, po challenged with Dopa after 4 hrs compound treatment1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1149162Hypnotic activity in cat assessed as increase in total sleep time at 0.25 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193385Percentage decrease in systolic blood pressure after 1 hr at 1 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149219Antiulcer activity in albino Sprague-Dawley rat stress ulcer model assessed as prevention of stress-induced gastric lesions by measuring ulcer index score at 40 mg/kg, po administered 30 mins prior to stress measured after 4 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID195165The compound was tested for hyperexcitability in rat at a dose of 20 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149223Antiulcer activity in albino Sprague-Dawley rat shay ulcer model assessed as ulcer index scores at 50 mg/kg administered intraduodenally post pyloric ligation measured after 18.5 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193393Percentage decrease in systolic blood pressure after 24 hr at 30 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1150010Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1149124Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 4 mg/kg, po after 2 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193525Percentage decrease in systolic blood pressure after 4 hr at 30 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID180983percentage decrease in heart rate after 24 hr at a dose of 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193398Percentage decrease in systolic blood pressure after 4 hr at 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID132466The compound was tested for analgesic activity using writhing (W) test in mouse1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID180981percentage decrease in heart rate after 1 hr at a dose of 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1150019Antipsychotic activity in Long-Evens rat assessed as reduction in methamphetamine-induced hyperactivity at 5 mg/kg, po1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID193392Percentage decrease in systolic blood pressure after 24 hr at 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149137Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 20 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149214Antiulcer activity in albino Sprague-Dawley rat reserpine ulcer model assessed as prevention of reserpine-induced gastric lesions by measuring ulcer index scores at 10 mg/kg, po administered 30 mins prior to reserpine challenge measured after 6 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID140544The compound was tested for activity to decrease fighting in mouse at a dose of 10 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149158Hypnotic activity in cat assessed as increase in total sleep time at 0.5 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193386Percentage decrease in systolic blood pressure after 1 hr at 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID180985percentage decrease in heart rate after 24 hr at a dose of 1 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149220Antiulcer activity in albino Sprague-Dawley rat reserpine ulcer model assessed as prevention of reserpine-induced gastric lesions by measuring ulcer index scores at 50 mg/kg, po administered 30 mins prior to reserpine challenge measured after 6 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193539The compound was tested for decreasing motor activity in rat at a dose of 4 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149171Hypnotic activity in cat assessed as decrease in non-REM sleep time at 0.5 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149172Antisecretory activity in Sprague-Dawley rat assessed as decrease in volume at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193535The compound was tested for decreasing motor activity in rat at a dose of 1 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1150009Analgesic activity in po dosed Sprague-Dawley rat by tail flick assay1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1150015Antianxiety activity in Long-Evens rat assessed as decrease in motor activity at 10 mg/kg, po by tranquilizer activity test1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1150027Sedative-hypnotic activity in cat assessed as change in total sleep time at 0.5 mg/kg, po after 12 hrs1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID180995percentage decrease in heart rate after 4 hr at a dose of 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID180354The compound was tested for analgesic activity using (RTF) tail-flick test in rat1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID193547The compound was tested for methamphetamine antagonism in rat at a dose of 80 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID180840percentage decrease in heart rate after 1 hr at a dose of 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149148Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 0.3 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149115Antianxiety activity in albino BALB/cJ mouse assessed as reduction in footshock-induced fighting behavior at 10 mg/kg, po after 30 to 90 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193387Percentage decrease in systolic blood pressure after 1 hr at 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149170Hypnotic activity in cat assessed as increase in non-REM sleep time at 0.25 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149103Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing administered 30 mins prior to acetic acid challenge measured after 5 mins for 20 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID180838percentage decrease in heart rate after 1 hr at a dose of 0.3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193395Percentage decrease in systolic blood pressure after 4 hr at 1 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID180992percentage decrease in heart rate after 4 hr at a dose of 0.3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193529Percentage decrease in systolic blood pressure after 6 hr at 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193545The compound was tested for methamphetamine antagonism in rat at a dose of 20 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1149131Antianxiety activity in po dosed dog assessed as ataxia administered as single dose measured up to 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID180842percentage decrease in heart rate after 1 hr at a dose of 1 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193388Percentage decrease in systolic blood pressure after 1 hr at 30 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID181005percentage decrease in heart rate after 6 hr at a dose of 0.3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID181015percentage decrease in heart rate after 6 hr at a dose of 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID180991percentage decrease in heart rate after 24 hr at a dose of 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID181002percentage decrease in heart rate after 4 hr at a dose of 30 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193389Percentage decrease in systolic blood pressure after 24 hr at 0.3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID157897In vitro intrinsic binding affinity at platelet activating factor receptor using rabbit platelet membranes1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists.
AID195166The compound was tested for hyperexcitability in rat at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID180982percentage decrease in heart rate after 24 hr at a dose of 0.3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193530Percentage decrease in systolic blood pressure after 6 hr at 3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149105Analgesic activity in po dosed Sprague-Dawley rat after 15 to 90 mins by tail flick test1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID181007percentage decrease in heart rate after 6 hr at a dose of 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193531Percentage decrease in systolic blood pressure after 6 hr at 30 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149215Antiulcer activity in albino Sprague-Dawley rat shay ulcer model assessed as ulcer index scores at 20 mg/kg administered intraduodenally post pyloric ligation measured after 18.5 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149218Acute toxicity in po dosed mouse1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID193384Percentage decrease in systolic blood pressure after 1 hr at 0.3 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID180979percentage decrease in heart rate after 1 hr at a dose of 30 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149195Antisecretory activity in Sprague-Dawley rat assessed as decrease in pepsin output at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1150012Antianxiety activity in albino BALB/cJ mouse assessed as decrease in foot shock-induced fighting behavior at 10 mg/kg, po by tranquilizer activity test1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID181009percentage decrease in heart rate after 6 hr at a dose of 1 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193396Percentage decrease in systolic blood pressure after 4 hr at 10 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID193390Percentage decrease in systolic blood pressure after 24 hr at 1 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (71.43)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.95 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		2.1310adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		1.9510organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		1.95101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
ellipticine
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.		2.1310indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.1310aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
tolazoline hydrochloride
[no description available]		2.1310benzenes
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		2.1310antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
emetine
Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.		2.1310isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
2-fluoroadenine
2-fluoroadenine : An organofluorine compound that is adenine in which the hydrogen at position 2 (the carbon between the two nitrogens of the pyrimidine ring) is replaced by a fluorine.		2.1310organofluorine compound;
purines		antineoplastic agent
hydroxychloroquine sulfate
[no description available]		2.1310
diphenoxylate
Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.		1.9510ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine		antidiarrhoeal drug
c 137
C 137: RN given refers to parent cpd		2.1310
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		2.8740benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
imidocarb
Imidocarb: One of ANTIPROTOZOAL AGENTS used especially against BABESIA in livestock. Toxicity has been reported.		2.1310ureasantiprotozoal drug
metoprine
metoprine: histamine methyltransferase antagonist		2.1310
parbendazole
parbendazole: anthelmintic used against a variety of gastrointestinal parasites; minor descriptor (75-86); on-line & INDEX MEDICUS search BENZIMIDAZOLES; RN given refers to parent cpd		2.1310benzimidazoles;
carbamate ester
levamisole
Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.		2.13106-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
thymolphthalein
Thymolphthalein: Used as a pH indicator and as a reagent for blood after decolorizing the alkaline solution by boiling with zinc dust.		2.1310terpene lactone
3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6h-dibenzo(b,d)pyran-1-ol
3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran-1-ol: synthetic surrogate of tetrahydrocannabinol; structure		1.9510
triazinate
triazinate: structure		2.1310
piritrexim
piritrexim: RN given refers to parent cpd; structure given in first source		2.1310
web 2086
WEB 2086: structure given in first source; PAF antagonist		1.9810organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
flucofuron
flucofuron: structure given in first source. flucofuron : A member of the class of phenylureas that is urea in which each nitrogen is substituted by a 4-chloro-3-(trifluoromethyl)phenyl group.		2.1310(trifluoromethyl)benzenes;
monochlorobenzenes;
organochlorine pesticide;
organofluorine pesticide;
phenylureas		epitope
epiroprim
epiroprim: an analog of trimethoprim with improved antimicrobial and pharmacokinetic properties; structure given in first source		2.1310
2,2',2''-terpyridine
2,2',2''-terpyridine: RN given refers to parent cpd. 2,2':6',2''-terpyridine : A tridentate heterocyclic ligand that binds metals at three meridional sites giving two adjacent 5-membered MN2C2 chelate rings.		2.1310terpyridineschelator
chaparrinone
chaparrinone: quassinoid which inhibits protein sunthesis & DNA synthesis in cells; structure in first source		2.1310triterpenoid
thianthrene 5-oxide
thianthrene 5-oxide: used as a probe of the electrophilicity of hemoprotein oxidizing species; structure given in first source		2.1310
tryptanthrine
tryptanthrine: minor constituent of traditional Chinese medicine qing dai		2.1310alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound
ro 22-3581
[no description available]		2.1310
chloroquine diphosphate
[no description available]		2.1310
ethylhydrocupreine
ethylhydrocupreine: structure; RN given refers to parent cpd. optochin : A cinchona alkaloid consisting of 10,11-dihydrocinchonan bearing hydroxy and ethoxy substituents at positions 9 and 6' respectively.		2.1310aromatic ether;
cinchona alkaloid		EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
cinchonine
[no description available]		2.1310(8xi)-cinchonan-9-ol;
cinchona alkaloid		metabolite
wr 158122
WR 158122: structure		2.1310
abbott 40174
Abbott 40174: tetrahydropyridobenzopyran derived from cannabinoid nucleus; structure		2.8740
3-heptyl-4-hydroxy-7-methoxy-2-methylquinoline
3-heptyl-4-hydroxy-7-methoxy-2-methylquinoline: structure given in first source		2.1310
cinchonidine
cinchonidine: has antimalarial activity; diastereoisomer of cinchonine with distinct physiochemical properties; RN given refers to parent cpd(8alpha,9R)-isomer. cinchonidine : 8-epi-Cinchonan in which a hydrogen at position 9 is substituted by hydroxy (R configuration). A diasteroisomer of cinchonine, it occurs in the bark of most varieties of Cinchona shrubs, and is frequently used for directing chirality in asymmetric synthesis.		2.1310(8xi)-cinchonan-9-ol;
cinchona alkaloid		metabolite
methotrexate
[no description available]		2.1310dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
my 12-62c
MY 12-62c: from Pseudomonas methanica KY4634. 2-heptyl-4-quinolone : A quinolone consisting of quinolin-4(1H)-one carrying a heptyl substituent at position 2.. 2-heptyl-4-hydroxyquinoline : A monohydroxyquinoline that is 4-hydroxyquinoline bearing an additional heptyl substituent at position 2.		2.1310monohydroxyquinoline;
quinolone		antibacterial agent;
iron chelator;
metabolite;
signalling molecule
anisomycin
Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.		2.1310monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		2.1310cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
pseudolycorine
pseudolycorine: alkaloid isolated from Narcissus tazetta var. chinensis Roem, N. papyraceus or Lycoris radiata Herb; structure in first source		2.1310phenanthridines
jp-1302
[no description available]		2.1310
TCMDC-138263
[no description available]		2.1310harmala alkaloid
2,6-bis(benzimidazol-2-yl)pyridine
2,6-bis(benzimidazol-2-yl)pyridine: structure in first source		2.1310benzimidazoles
n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine
N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: an SK channel inhibitor		2.1310
2-[4-chloro-5-(cyclopentylsulfamoyl)-2-methylphenoxy]-N-cyclohexylacetamide
[no description available]		2.1310sulfonamide
stk295900
[no description available]		2.1310
6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole
[no description available]		2.1310benzimidazoles
1-(4-fluorophenyl)-3-[4-(4-fluorophenyl)-2-methyl-5-(trifluoromethyl)-3-pyrazolyl]urea
[no description available]		2.1310pyrazoles;
ring assembly
dimethyl-heptyl tetrahydrocannabinol
dimethyl-heptyl tetrahydrocannabinol: structure given in first source		1.9510
azoxystrobin
azoxystrobin: a methoxyacrylate analog; a strobilurin fungicide; structure given in first source. azoxystrobin : An aryloxypyrimidine having a 4,6-diphenoxypyrimidine skeleton in which one of the phenyl rings is cyano-substituted at C-2 and the other carries a 2-methoxy-1-(methoxycarbonyl)vinyl substituent, also at C-2. An inhibitor of mitochondrial respiration by blocking electron transfer between cytochromes b and c1, it is used widely as a fungicide in agriculture.		2.1310aryloxypyrimidine;
enoate ester;
enol ether;
methoxyacrylate strobilurin antifungal agent;
methyl ester;
nitrile		antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
quinone outside inhibitor;
xenobiotic
trequinsin hydrochloride
[no description available]		2.1310
N-[4-(1H-benzimidazol-2-yl)phenyl]-4-ethoxy-3-nitrobenzamide
[no description available]		2.1310benzimidazoles
2-[2-methoxyethyl-(1-oxo-2-thiophen-2-ylethyl)amino]-N-[(4-methoxyphenyl)methyl]-2-(4-propan-2-ylphenyl)acetamide
[no description available]		2.1310monoterpenoid
7-chloro-N-(phenylmethyl)-4-quinolinamine
[no description available]		2.1310aminoquinoline
5-[(5-bromo-2-hydroxyphenyl)-oxomethyl]-1-cyclohexyl-2-oxo-3-pyridinecarbonitrile
[no description available]		2.1310aromatic ketone
imd 0354
N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source		2.1310benzamides
daphnetin
[no description available]		2.1310hydroxycoumarin
hispidulin
hispidulin : A monomethoxyflavone that is scutellarein methylated at position 6.		2.1310monomethoxyflavone;
trihydroxyflavone		anti-inflammatory agent;
anticonvulsant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
plant metabolite
morusin
morusin: from Morus root bark; structure given in first source. morusin : An extended flavonoid that is flavone substituted by hydroxy groups at positions 5, 2' and 4', a prenyl group at position 3 and a 2,2-dimethyl pyran group across positions 7 and 8.		2.1310extended flavonoid;
trihydroxyflavone		antineoplastic agent;
plant metabolite
olvanil
[no description available]		2.1310methoxybenzenes;
phenols
pd 166285
[no description available]		2.1310
pd-173952
[no description available]		2.1310
10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one
[no description available]		2.1310pyridochromene
diphenoxylate hydrochloride
diphenoxylate hydrochloride : The hydrochloride salt of diphenoxylate.		1.9510hydrochlorideantidiarrhoeal drug
bvt.948
[no description available]		2.1310
edatrexate
edatrexate: structure given in first source		2.1310glutamic acid derivative
pq 401
PQ 401: an IGF receptor type I antagonist; structure in first source		2.1310quinolines
nik 12192
4-(5,6-dichloro-1H-indol-2-yl)-3-ethoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzamide: structure in first source		2.1310
zm 447439
ZM447439 : A member of the class of quinazolines that is quinazoline which is substituted at positions 4, 6 and 7 by a (4-benzamidophenyl)nitrilo group, methoxy group and a 3-(morpholin-4-yl)propoxy group, respectively. It is an ATP-competitive inhibitor of Aurora A and Aurora B kinases with IC50 of 110 nM and 130 nM, respectively.		2.1310aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor
pha 665752
[no description available]		2.1310dichlorobenzene;
enamide;
indolones;
N-acylpyrrolidine;
pyrrolecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide		antineoplastic agent;
c-Met tyrosine kinase inhibitor
zstk474
ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase.		2.1310benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
brl 15572
BRL 15572: specific for h5-HT(1D) receptors; structure in first source. 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol hydrochloride : A hydrochloride that is the monohydrochloride salt of 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol. A selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.		2.1310hydrochlorideprodrug;
serotonergic antagonist
amodiaquine hydrochloride
[no description available]		2.1310
morphine sulfate
[no description available]		1.9510alkaloid sulfate salt
puromycin dihydrochloride
[no description available]		2.1310
au-1
[no description available]		2.1310
1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea
[no description available]		2.1310quinazolines
1843u89
1843U89: structure given in first source; a folate analog		2.1310
hesperadin
[no description available]		2.1310
cb 3717
[no description available]		2.1310N-acyl-L-glutamic acid
cb 3705
CB 3705: inhibitor of dihydrofolate reductase & thymidylate synthetase		2.1310
ConditionIndicatedRelationship StrengthStudiesTrials
Ataxia
Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.		01.9510
Gastric Ulcer
[description not available]		01.9510
Aggression
Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.		02.3620
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		01.9510
Circulatory Collapse
[description not available]		01.9810
Shock
A pathological condition manifested by failure to perfuse or oxygenate vital organs.		01.9810
Blood Pressure, High
[description not available]		01.9610
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		01.9610
Plasmodium falciparum Malaria
[description not available]		02.1310
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.1310
Glaucoma
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)		03.3411
Intraocular Pressure
The pressure of the fluids in the eye.		03.3411